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Sinusoidal obstruction syndrome or veno-occlusive disease (SOS/VOD) is a potentially life-threatening complication of
hematopoietic SCT (HSCT). This review aims to highlight, on behalf of the European Society for Blood and Marrow Transplantation,
the current knowledge on SOS/VOD pathophysiology, risk factors, diagnosis and treatments. Our perspectives on SOS/VOD are (i) to
accurately identify its risk factors; (ii) to deﬁne new criteria for its diagnosis; (iii) to search for SOS/VOD biomarkers and (iv) to
propose prospective studies evaluating SOS/VOD prevention and treatment in adults and children.
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INTRODUCTION
Sinusoidal obstruction syndrome (SOS), previously known as veno-
occlusive disease (VOD; referred to as SOS/VOD hereafter), is a
potentially life-threatening complication observed after hemato-
poietic SCT (HSCT).1 In this syndrome, sinusoidal endothelial cells
and hepatocytes in the zone 3 of the hepatic acinus are damaged
by toxic metabolites generated during the conditioning regimen.2
Diagnosis of SOS/VOD is based on clinical criteria including weight
gain, ﬂuid retention with ascites, tender hepatomegaly and
jaundice.3–5 The condition usually develops by 30 days after
HSCT, although it can occur later. Historically, its reported
incidence ranges from approximately 5 to 60%, and this variation
is clearly not only related to the intensity of the conditioning
regimen, the type of transplant and the presence of risk factors,
but also on the clinical criteria used for SOS/VOD diagnosis.3,4,6–8
Nowadays, SOS/VOD is more common after allogeneic HSCT
(allo-HSCT) conditioned with myeloablative conditioning regimen
(MAC), with an incidence around 10–15%, against o5% after
allo-HSCT conditioned with reduced intensity conditioning
regimen and autologous HSCT (auto-HSCT).5,7,8 The SOS/VOD
severity varies widely from mild forms, which are resolved within a
few weeks, to a severe syndrome, deﬁned by the presence of
multi-organ failure, and associated with a high mortality rate
(480%).5 For this reason, despite the relatively low incidence
of this complication, a better understanding of SOS/VOD
pathophysiology and risk factors is indispensable to improving
prevention and treatment of potentially life-threatening severe
SOS/VOD.
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The aim of this work is to summarize the evidence on SOS/VOD
pathophysiology, risk factors and treatment, with a special focus
on current studies, and to discuss future prospects to improve our
knowledge and management of SOS/VOD, on behalf of the
European Society for Blood and Marrow Transplantation (EBMT).
PATHOPHYSIOLOGY
It is now clearly established that the ﬁrst morphological change in
SOS/VOD occurs in the sinusoidal endothelial cells, leading to the
obstruction of the hepatic sinusoids in the zone 3 of the hepatic
acinus (Figure 1). Endothelial cell lesions after HSCT are not limited
to those lining the sinusoids and can lead to a wide range of
endothelial syndromes early after transplant, including SOS/VOD,
capillary leak syndrome, engraftment syndrome, transplant-
associated microangiopathy or diffuse alveolar hemorrhage.2
The proposed hypothesis to explain the SOS/VOD pathophy-
siology during HSCT is that sinusoidal endothelial cells can be
activated and damaged by factors such as the chemotherapy or
radiotherapy included in the conditioning regimen, cytokines
produced by the injured tissues, endogenous microbial products
translocated through damaged mucosal barriers,9 drugs used
during the procedure (such as granulocyte colony-stimulating
factors or calcineurin inhibitors)10,11 and the complex process of
engraftment. All these factors produce a physiological activation
of the endothelial cells (Figure 2a); however, if they are intense
and sustained, such activation can evolve to endothelial damage:
sinusoidal endothelial cells round up, favoring the appearance of
gaps in the sinusoidal barrier2 (Figure 2b). These changes facilitate
the egress of RBCs, leucocytes and cellular debris into the space of
Disse beneath the endothelial cells and dissect the endothelial
lining (Figure 2c). Finally, the sloughed sinusoidal lining embolizes
downstream and obstructs sinusoidal ﬂow (Figure 2d). In these
early stages, histological examinations show thickening of the
subintimal zone, which leads to the narrowing of the venular
lumen and an increased resistance to blood ﬂow.12 This
contributes to the post-sinusoidal portal hypertension, worsening
liver dysfunction and ascites seen in the disease, eventually
resulting in multi-organ failure (characterized by pulmonary and
renal dysfunction, as well as encephalopathy) and death.5
Endothelial activation after HSCT conditioning, particularly in
the allogeneic setting, is associated with a prothrombotic state,
demonstrated by an increase of von Willebrand factor expression
and platelet adhesion.13 Furthermore, whereas pro-inﬂammatory
and pro-apoptotic changes on epithelial cells decrease after day
14 in auto-HSCT,14 they continue to increase in the allo-HSCT
setting,14 highlighting that alloreactivity could contribute to
endothelial damage after conditioning.15 Vascular endothelial
cells constitute a target for blood-borne executors of the immune
system, antibodies and T cells, and several experimental models
suggest that vascular endothelial cells are targets for alloreactive
T cells in acute and chronic GVHD.16 Furthermore, the immunos-
suppressive therapy used after allo-HSCT has an effect on
endothelial cells: CsA, compared with tacrolimus and sirolimus,
has been shown to increase adhesion molecules in vitro, which
could contribute to SOS/VOD.17 Overall, these observations are in
accordance with the increased incidence of SOS/VOD after allo-
HSCT compared with auto-HSCT.5
Finally, although the ﬁrst morphological change in SOS/VOD
occurs in the sinusoidal endothelial cells, hepatocyte dysfunction
also contributes directly to SOS/VOD pathophysiology. Hepato-
cytes, through the glutathione enzymatic system, have an
important role in the elimination of several drugs, such as
CY.18,19 Previous liver disease, BU, TBI, all impair this system,
leading to the accumulation of CY metabolites, which will injure
sinusoidal endothelial cells but also hepatocytes.18
RISK FACTORS
Known SOS/VOD risk factors are listed Table 1. Some are directly
transplant-related, such as the choice of the stem cell source, of
the conditioning regimen and of the GVHD prophylaxis. As
expected, because alloreactivity contributes to endothelium
damage and SOS/VOD pathophysiology, the risk of SOS/VOD is
higher where alloreactivity is higher: after allo-HSCT compared
with auto-HSCT,5,6 with unrelated donors and HLA-mismatched
donors, and in non-T-cell depleted allo-HSCT.20,21 The condition-
ing regimen intensity and drugs used also inﬂuence SOS/VOD risk:
the risk is higher after conventional MAC compared with reduced
intensity conditioning.5,22,23 The use of high dose (⩾12 Gray) or
unfractionated TBI increases the risk of SOS/VOD.6 Similarly, BU,
particularly in combination with CY is associated with an increased
risk of SOS/VOD.6 No signiﬁcant difference of SOS/VOD is reported
when CY is associated with either TBI or oral BU.24 The risk of
SOS/VOD is higher in patients receiving a second allo-HSCT.
Regarding immunosuppressive therapy, its more controversial
data suggest that sirolimus is associated with SOS/VOD after MAC
TBI-based allo-SCT when used in combination with MTX.25
In contrast, preclinical data highlight the detrimental role of
















Figure 1. Schematic representation of the hepatic acinus. In sinusoidal obstruction syndrome, obstruction of the hepatic sinusoids occurs in
the zone 3 of the hepatic acinus.
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immunosuppressive therapy effect exerted on epithelial cells
probably depends on treatment association and of the condition-
ing regimen used.
Some of the SOS/VOD risk factors are directly linked to patients’
and disease characteristics. Older age, impaired Karnofsky status
(o90) and advanced disease (beyond second CR or relapse/
refractory disease) have been reported as SOS/VOD risk factors.6
An increased risk of SOS/VOD in women has also been reported;
however, that was probably related to the use of progestin
therapy to prevent gynecological bleeding, as the incidence of
SOS/VOD was higher in women who received norethisterone as
compared with those who did not.26 The development of reduced
intensity conditioning allowed us to perform allo-HSCT in patients
with co-morbidities who would otherwise be ineligible for
this procedure, but this led to an increase in the number of
patients presenting risk factors, such as metabolic syndrome
and, particularly, obesity. Genetic polymorphism (GSTM1 and
GSMTT1,27 heparanase in children28), deﬁcit in antithrombine III29
or tissue plasminogen activator30 and resistance to the activated C
protein29 are associated with increased risk of SOS/VOD. In the
pediatric setting, higher incidence of SOS/VOD is seen in the
primary hemophagocytic lymphohistiocytosis, adrenoleucodystro-
phy osteopetrosis or thalassemia major, auto-HSCT in patients
with neuroblastoma, younger age (under 1–2 years of age)
and low weight.31–33 Importantly, outside the transplant setting,
SOS/VOD is observed in patients treated with actinomycin D
and also infants in particular when treated with high-dose
chemotherapy regimens.
Previous hepatic disease is one of the main risk factors
of SOS/VOD. Thus, liver function abnormalities, such as
serum transaminase42.5 upper limit of normal6,34 or serum
bilirubin41.5 upper limit of normal, active hepatic diseases
such as cirrhosis, hepatic ﬁbrosis or active viral hepatitis are
SOS/VOD risk factors. However, hepatic dysfunction may be
totally asymptomatic and result from previous hepatotoxic
treatment including gemtuzumab ozogamicin35 and abdominal
irradiation,6,34 or from concomitant hepatotoxic drugs such as
azole. Finally, iron overload has also been identiﬁed as an
SOS/VOD risk factor.
DIAGNOSIS
Given the high mortality rate (480%) associated with severe
SOS/VOD syndrome,5 a daily and strict monitoring to detect early
symptoms and signs of SOS/VOD should be performed from the
start of conditioning and at least up to day 14 after HSCT.8 Special
attention should be paid to patients presenting one of the risk
factors mentioned above. Patients must be monitored daily for
weight gain, ﬂuid retention, overt edema and ascites, hepatome-
galy and jaundice.8 Nurses are indispensable in this daily
monitoring, not just to weigh patients daily combined with a
meticulous ﬂuid balance, but also to monitor ﬂuid intake and
output as well as being alert to more unspeciﬁc symptoms such as
a b
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Figure 2. Sinusoidal obstruction syndrome pathogenesis. (a) Normal hepatic sinusoid; (b) sinusoidal endothelial cells damaged during
conditioning round up favoring the appearance of gaps in the sinusoidal barrier; (c) RBCs, leucocytes and cellular debris penetrate into the
space of Disse detaching the endothelial lining; (d) the sloughed sinusoidal lining cells embolize downstream and obstruct the sinusoidal ﬂow
(sinusoidal obstruction syndrome). Adapted from 'The role of the endothelium in the short-term complications of hematopoietic SCT' by E
Carreras and M Diaz-Ricart.2
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abdominal discomfort and pain. For successful prevention,
identiﬁcation, diagnosis and treatment of SOS/VOD team work is
necessary and nurses should receive speciﬁc education on SOS/
VOD to understand the importance of their role. Although
jaundice is usually present in adults,3 it can be absent in SOS/
VOD developing late after HSCT, and is often absent in children.36
Other ﬁndings have been associated with SOS/VOD, such as
symptoms related to ﬂuid retention (pleural effusion, pulmonary
inﬁltrate, hypoxia). New onset of transfusion-refractory thrombo-
cytopenia with rapid consumption of transfused platelets not
explained by concomitant conditions like sepsis early during HSCT
can be the earliest sign of SOS/VOD reﬂecting the endothelial
nature of the pathophysiology of SOS/VOD.8 The presence of renal
and/or pulmonary dysfunction (or, less frequently, central nervous
system involvement with encephalopathy) deﬁnes a multi-organ
failure and severe SOS/VOD.37
To facilitate the diagnosis of SOS/VOD, two different sets of
clinical criteria have been described: the revised Seattle3,34 and the
Baltimore criteria.4 These are based on the presence of clinical
ﬁndings (jaundice, weight gain, hepatomegaly and ascites) not
attributable to any other possible cause, in the ﬁrst 3 weeks after
HSCT. However, neither set of criteria considers the cases of late
SOS/VOD appearing after day +21 and up to day +40 to +50.
Furthermore, the use of these criteria for SOS/VOD diagnosis may be
an issue when only edema and weight gain are present. Bearman
et al.38 developed a model to predict the risk of developing severe
SOS/VOD, based on serum bilirubin and percentage weight gain at
different time points subsequent to HSCT, up to day +16. Although
interesting, this model is limited to MAC (TBI CY, BU CY or CY, BCNU,
VP-16), and therefore its utility is limited.
New onset of ultrasound-conﬁrmed ascites and/or hepatome-
galy and attenuated or reversed hepatic venous ﬂow by
ultrasound are more speciﬁc criteria, whereas gall bladder wall
thickening despite being non-speciﬁc may be helpful for SOS/VOD
diagnosis.39 Indeed, most accurate methods to conﬁrm the
diagnosis of SOS/VOD (measurement of the hepatic venous
gradient pressure through the jugular vein, liver biopsy) are
invasive and difﬁcult to perform in routine practice.40
TREATMENT
Preventive therapy
Adoption of preventive measures that could reduce SOS/VOD
incidence and/or severity is indispensable, especially because we
do not have therapeutic measures with 100% efﬁcacy in this
life-threatening disease. Preventive measures combine two
approaches: reversal of SOS/VOD risk factors (Table 1) and
pharmacological prevention.
Most patient- and hepatic-related risk factors are impossible to
reverse, and patients with such risks should be included in
prophylactic programs. In those with a reversible condition (acute
hepatitis, active disease), delay of the HSCT until its resolution
should be discussed according to the disease status. Effort must
be made to avoid any hepatotoxic concomitant drug,8 even if it is
most of the case impossible. There is often no alternative to
the use of gemtuzumab ozogamicin, however, splitting dose
(3 mg/m2) probably allows a decrease of the SOS/VOD risk.
Transplant-related risk factors are easier to modify.8 The use of
reduced intensity conditioning allo-HSCT has decreased the
incidence of SOS/VOD and should be considered in elderly
patients and in adult patients heavily pre-treated or with co-
morbidities. It is also possible to reduce the toxicity of MAC,
combining i.v. BU and ﬂudarabine, instead of the classical oral BU
and CY.23,41,42 Oral BU may be replaced by the equally effective i.v.
BU, which has a predictable pharmacokinetic proﬁle, is easy to
monitor and reduces the incidence of SOS/VOD.19 In children, in
infants, in particular, the use of BU serum level measurements can
be helpful to reduce the prominent interpatient variability.
Similarly, based on the pathophysiology of SOS/VOD, a change
in the order of the drugs (CY/BU instead of BU/CY) may decrease
the risk of SOS/VOD.43 For a TBI-based MAC regimen, hyper-
fractionated TBI is strongly recommended. Efforts should also be
made to reduce the risk of allo-reactivity; donors with the
maximum degree of compatibility or the use of T-cell-depleted
grafts are recommended.20,21
The third approach is to employ pharmacological measures to
prevent SOS/VOD. The use of heparin is still very controversial.
A meta-analysis evaluated patients who received either unfractio-
nated heparin or low-molecular-weight heparin for SOS/VOD
prevention.44 Twelve studies (2782 patients) were eligible. Overall,
meta-analysis is negative: anticoagulation prophylaxis was asso-
ciated with a non-signiﬁcant decrease in the risk of SOS/VOD
(pooled relative risk, 0.90; 95% conﬁdence interval, 0.62–1.29).
However, among the three randomized trials analyzed in the
meta-analysis, two (one with unfractionated heparin45 and one
with low-molecular-weight heparin46) showed a beneﬁcial effect
of heparin, and results of the third randomized study47 may have
been affected by the delayed introduction of anticoagulation on
the day of marrow infusion rather than at conditioning. Although
bleeding was reported as an adverse event in 7 of the 12 studies
under the meta-analysis, in none of them was it found to be more












Older4younger (in adult patients)
Female receiving norethisterone
Karnofsky score below 90%
Gene polymorphism (GSTM1, GSMTT1, heparanase)
Advanced disease (beyond second CR or relapse)
Metabolic syndrome
Deﬁcit of AT III, t-PA and resistance to activated protein C
Thalassemia







Previous use of gemtuzumab ozogamicin
Use of hepatotoxic drugs
Iron overload
Pediatric speciﬁc risk factors
Hemophagocytic lymphohistiocytosis, adrenoleucodystrophy,
osteopetrosis
High-dose auto-HSCT in neuroblastoma
Young age (under 1–2 years of age)
Low weight
Juvenile myelo-monocytic chronic leukemia
Abbreviations: AT III= antithrombin III; HSCT=hematopoietic SCT;
SOS/VOD= sinusoidal obstruction syndrome or veno-occlusive disease;
t-PA= tissue plasminogen activator; ULN=upper limit of normal.
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frequent in the anticoagulant group compared with the control
group.44 Large randomized control studies are indispensable to
properly evaluate heparin use and to enable deﬁnitive recom-
mendation for its continuation or abandonment for SOS/VOD
prevention. At present, heparin remains used for SOS/VOD
prevention in some EBMT centers.
Data on the usefulness of ursodeoxycholic acid for SOS/VOD
prevention are non-conclusive: some randomized trials suggest
that it decreases the incidence of SOS,48–50 whereas others fail to
demonstrate an advantage.51,52 However, patients receiving this
prophylaxis have less liver toxicity, less acute GVHD and better
survival, strongly suggesting the beneﬁcial effect of ursodeoxy-
cholic acid.52 Furthermore, it has been shown that ursodeoxy-
cholic acid use is associated with a decrease of non-relapse
mortality.53 Finally, a prospective phase III study recently showed a
reduced incidence of SOS/VOD in pediatric HSCT patients who
received prophylaxis deﬁbrotide (DF).
Curative therapy
The ﬁrst step in the treatment of SOS/VOD is symptomatic.8 Given
SOS/VOD is a life-threatening disease, therapy must be started as
soon as possible. Fluid and sodium balance and careful use of
diuretics (spironolactone or furosemide), should be introduced at
the ﬁrst suspicion, when SOS/VOD is still only probable.8 Several
symptomatic measures can be used to reduce the discomfort
produced by massive ascites or pleural effusions, starting with
oxygen therapy.8 In particular, in infants, when massive ascites is
threatening respiration via pulmonary displacement, early perito-
neocentesis can be extremely helpful to avoid complications
associated with assisted ventilation. When ﬂuid accumulation and
renal failure cannot be controlled, hemodialysis/hemoﬁltration is
required.8 Severe SOS/VOD treatment requires transfer into an
intensive care unit. A transjugular intrahepatic portosystemic
shunt should be discussed for patients with less advanced SOS/
VOD54 and hepatic transplantation in most severe diseases.55
Besides these symptomatic measures for SOS/VOD, the only
proven curative treatment so far is DF.
FOCUS ON DF
Treatment of SOS/VOD with DF
DF is a polydisperse oligonucleotide with local antithrombotic,
anti-ischemic and anti-inﬂammatory activity,56 which has protec-
tive effects on the small vessel endothelium. Although its precise
mechanism of action in SOS/VOD remains under investigation, it
seemingly involves two distinct elements: the protection of
endothelial cells and restoration of the thrombotic-ﬁbrinolytic
balance.
Several studies evaluating DF in SOS/VOD over the last 15 years
are summarized in Table 2. In a prospective randomized
multicenter dose ﬁnding phase II trial,57 adult and pediatric
patients with severe SOS/VOD after HSCT were randomized to
receive either a lower-dose (25 mg/kg per day, n= 75) or a higher-
dose (40 mg/kg per day, n= 74) of DF. There were no signiﬁcant
differences between the two arms regarding CR rate (49 vs 43%;
P= 0.613) and day +100 OS (44 vs 39%; P= 0.619). DF was
generally well tolerated, but a trend towards more toxicity was
seen with the 40-mg/kg per day dose, particularly among the
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per day) from start conditioning to 30 days post HSCT (at
least 14 days if discharge before).






related mortality: DF 2%,
control 6%, P= 0.10
No difference in AEs and
haemorrhagic AEs
Abbreviations: AE= adverse event; CUP= compassionate use program; DF=deﬁbrotid; HC=historical control; HSCT=hematopoietic SCT; SAE= severe
adverse event; SOS/VOD= sinusoidal obstruction syndrome or veno-occlusive disease; T-IND= treatment-investigational new drug.
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pediatric patients. The lower dose of DF (25 mg/kg per day) was
therefore used in a phase III trial for the treatment of adult and
pediatric patients with severe SOS/VOD.58 Given the life-
threatening nature of SOS/VOD, a trial randomizing patients to
placebo or supportive care was rejected; therefore, in this phase III
trial, patients receiving DF (n= 102) were compared with historical
controls (n= 32). CR rate and day +100 OS were signiﬁcantly
improved in the DF arm (24% and 38%, respectively) compared
with the historical control group (9%; P= 0.013 and 25%; P= 0.034,
respectively). The incidence of hemorrhagic adverse events was
found to be similar between patients treated with DF vs historical
control (65 vs 69%).57 Additional data were obtained via a
treatment investigational new drug protocol that included 425
patients with SOS/VOD after HSCT: 284 with severe and 141 with
non-severe SOS/VOD.59 In the former group, the CR rate was 47%
and the day +100 OS was 48%. In patients with non-severe SOS/
VOD, these ﬁgures were 47% and 69%, respectively. All HSCT
children (⩽16 years) had higher CR rates as compared with adults
(41 vs 27%; P= 0.0038) and better survival (60 vs 49%; P= 0.0203).
The overall toxicity of DF was reported to be manageable: 22% of
patients experienced at least one adverse event, which primarily
consisted of hemorrhage (17%) and hypotension (4%). These
studies led to the approval in 2014 of DF for treatment of severe
SOS/VOD after HSCT in European countries by the European
Medicines Agency (EMA).
Prophylaxis of SOS/VOD with DF
A recent prospective phase III study evaluated DF for prophylaxis
of SOS/VOD in pediatric HSCT.36 The study population consisted of
356 patients at high risk of developing SOS/VOD after a MAC prior
to HSCT, with one or more risk factors for SOS/VOD. Patients were
randomized to receive prophylactic DF at 25mg/kg per day given
on the ﬁrst day of conditioning until day 30 post HSCT
(prophylaxis arm, n= 180) or not (control arm, n= 176). If patients
presented SOS/VOD according to the modiﬁed Seattle criteria in
the control arm, a cross over allowed those patients to received DF
until SOS/VOD resolution. Reduced incidence of SOS/VOD was
evident in the patients receiving DF compared with the control
group (12 vs 20%; P= 0.0488). There was no signiﬁcant difference
of SOS/VOD-associated mortality at day +100 after HSCT between
the DF and the control group (2 vs 6%; P= 0.10) most probably
because of the cross-over design as the trial was not powered for
this outcome. However, the mortality was four times higher in
patients with SOS/VOD than in those without it (25 vs 6%;
Po0.0001). In total, 207 serious adverse events were reported in
108 of 180 patients (60%) of the DF group against 203 in 103 of
176 patients (59%) in the control group. Hemorrhagic adverse
events were reported in nine patients from the DF group and in
seven from the control group. Interestingly, the day +100
cumulative incidence of acute GVHD incidence was signiﬁcantly
reduced in the DF group compared with the control group (47 vs
65%; P= 0.0046). This result was corroborated by the signiﬁcantly
reduced steroid use for treatment of acute GVHD in the DF group
(37 vs 48%; Po0.036).
No randomized prospective study evaluating SOS/VOD preven-
tion with DF has so far been reported in adult patients. However,
given the high rates of CR and OS at day +100 in patients who
received DF for treatment of SOS/VOD and the reduced incidence
of SOS/VOD with DF prophylaxis in the pediatric setting, SOS/VOD
prevention with DF in adult patients after HSCT appears to be an
attractive approach and should be evaluated in the context of a
randomized prospective trial.
CONTROVERSIAL ISSUES
HSCT has undergone important changes in terms of conditioning
regimens, donor and stem cell sources, patient and disease
characteristics and post-transplant supportive care.60 Therefore, a
more accurate identiﬁcation of SOS/VOD risk factors is necessary.
Should we consider all second allo-HSCT as a risk factor or only
myeloablative second allo-HSCT? We must acknowledge that
second transplants are often performed in more heavily pre-
treated patients with more advanced disease, when alternative
mismatched donors are more frequently used. All these para-
meters are in themselves SOS/VOD risk factors, highlighting the
higher probability of SOS/VOD after second allo-HSCT, whatever
the conditioning. Similarly, development of haploidentical allo-
HSCT with post-transplant CY61 raised a new issue. Given the high
degree of mismatch and the use of CY, an increased incidence of
SOS/VOD was expected in this setting; yet, so far, no center
reported such an increase. One explanation might be the
administration of CY after allo-HSCT, far apart in time from the
conditioning. Furthermore, despite the use of haploidentical
donors, there is a decreased alloreactivity in these cases, thanks
to the use of post-transplant CY, as highlighted by the low
incidence of GVHD.61 Therefore, data are too preliminary to draw
deﬁnitive conclusion to consider or not haploidentical allo-HSCT
as a SOS/VOD risk factor. We must also question the role of the so-
called 'sequential' transplant approach, combining both intensive
chemotherapy and transplant conditioning within the same
procedure.62,63 This procedure is increasingly used in high-risk
patients such as relapse/refractory AML.62,63 So far, no data are
available regarding SOS/VOD incidence after sequential trans-
plant. However, an increased incidence of SOS/VOD is possible,
given the intensity of the chemotherapy delivered and that
patients receiving a sequential approach are often high-risk
heavily pretreated patients.62,63
BU is a well-established SOS/VOD risk factor. In the last decade,
reduced intensity and reduced toxicity conditioning regimens
have been developed with decreased doses of BU.41,64 Further-
more, i.v. BU has largely replaced oral BU and allow dose
adjustments thanks to pharmacokinetic monitoring. It raises the
question as to whether BU should be always considered as such a
risk factor regardless of the dose used, or whether a threshold
below which BU should no longer be considered as a risk factor
should be deﬁned.
The exact role of iron overload as a SOS/VOD risk factor is also a
matter of debate. Iron overload leads to hepatocyte and not to
sinusoidal endothelial cell lesion, the primary event in SOS/VOD
pathophysiology. Therefore, the increased incidence of SOS/VOD
in patients with iron overload is probably more related to multiple
transfusions and allo-immunization. Furthermore, iron overload
can lead to liver ﬁbrosis, which is a recognized risk factor for SOS/
VOD. Overall, iron overload remains as a risk factor for non-relapse
mortality after HSCT, and must be avoided or decreased.65 This, in
turn, raises the issue of iron chelation before HSCT: as it is a long-
term treatment, its potential beneﬁt should be carefully weighed
relatively to the risk of delaying the transplant. Furthermore, it is
so far difﬁcult to deﬁne a ferritin threshold below which HSCT can
be safely performed, similarly threshold are expected if liver
magnetic resonance imaging scan is recommended to accurately
evaluate iron overload.65,66
FUTURE PERSPECTIVES
The majority of SOS/VOD risk factors and currently used criteria for
SOS/VOD diagnosis (revised Seattle criteria and Baltimore
criteria)3,4,34 have been deﬁned more than 20 years ago, when
only MAC were used and no, truly effective, preventive or curative
drug for SOS/VOD existed. Since then, allo-HSCT has undergone
profound evolution with the development of alternative donors
and reduced intensity/toxicity regimen,41 and a new drug, DF, has
proven to be effective for the prevention and treatment of
SOS/VOD.56 These advances raise several issues, which remain to
be explored.
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First of all, deﬁnition of new diagnostic criteria seems
indispensable. Those criteria should be different for adults and
pediatric patients. In addition to the day of onset after HSCT,
weight gain and hyperbilirubinemia, new parameters such as
thrombocytopenia with rapid platelet consumption, or ultrasound
ﬁndings of ﬂow obstruction with Doppler evaluation should be
included. Overall, the main difﬁculty in the deﬁnition of a new
classiﬁcation to allow us to diagnose and treat SOS/VOD earlier is
the lack of sensitivity and speciﬁcity of the current criteria. An
attractive approach to circumvent this problem would be the
identiﬁcation of biomarkers of SOS/VOD, an area which is currently
under research. However, as allo-HSCT is very heterogeneous, the
hope to identify a biomarker valid in all settings appears unlikely
to be successful.
A prospective randomized trial evaluating SOS/VOD prophylaxis
with DF in adult patients is warranted. Such a trial should be
mainly aimed at patients with a high risk of developing SOS/VOD.
Given the action of DF on endothelial cells, it would be interesting
to evaluate not only the onset of SOS/VOD but also of any
endothelial syndromes (capillary leak syndrome, engraftment
syndrome, transplant-associated microangiopathy)2 and of acute
GVHD. Similarly, a comparable randomized trial in children would
be valuable given that the data from the ﬁrst trial were insufﬁcient
for DF approval in SOS/VOD children prophylaxis. Such studies
raise also the question of DF administration in out-patients, for
whom development of an oral formulation appears to be
essential. The optimal dose of DF employed for prophylaxis also
remains to be determined.
In summary, our future perspectives in the setting of SOS/
VOD are:
● More accurate identiﬁcation of SOS/VOD risk factors;
● Deﬁnition of new criteria for SOS/VOD diagnosis and grading;
● Identiﬁcation of potential biomarkers;
● Prospective trials evaluating endothelial syndrome prevention
with DF.
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